GLP-1 receptor agonists—like Ozempic, Wegovy, and Mounjaro—are making waves for their role in managing type 2 diabetes and aiding in weight loss. But beyond their medical benefits, these drugs are sparking a new conversation about their unexpected impact on skin. Rapid weight loss, a common outcome with GLP-1 drugs, has led to the rise of terms like “Ozempic face,” where the rapid shedding of fat changes the appearance of your face. So, how do these medications work, and what’s really happening to your skin?

How GLP-1 Drugs Work

GLP-1 drugs mimic a hormone in your body called glucagon-like peptide-1, which is naturally released in response to eating. This hormone stimulates insulin release to manage blood sugar levels, slows down digestion, keeping you full longer, and reduces hunger by acting on the brain.

These effects help people with type 2 diabetes control blood sugar, and for those using higher doses for weight loss, they can lead to significant, often rapid, reductions in weight. But with this fast weight loss comes visible changes in the skin, particularly on the face.

What Is “Ozempic Face“?

Rapid weight loss, whether from GLP-1 drugs or other methods, can result in a loss of fat from the face, leading to:

  • Hollow cheeks and a more gaunt appearance.
  • Wrinkles and fine lines becoming more pronounced.
  • Sagging skin, especially around the jawline and neck.
  • Sunken eyes, giving a tired look.

The skin doesn’t have time to adjust to the sudden loss of fat, and as we age, it becomes less elastic, making these changes more noticeable. While the term “Ozempic face” has gained popularity, these effects aren’t exclusive to GLP-1 drugs—they’re simply linked to the rapid pace of weight loss they often promote.

Why Does Rapid Weight Loss Affect Skin?

Your skin relies on fat to maintain volume and firmness. When fat is lost quickly, the skin’s structure is compromised, especially in areas like the face where fat loss is more visible. Unlike gradual weight loss, which gives the skin time to adapt, rapid weight loss can leave the skin looking deflated and less youthful.

Managing the Skin Effects of GLP-1 Drugs

While GLP-1 drugs are transforming weight loss and diabetes management, there are ways to minimize their impact on your skin:

  1. Lose Weight Gradually: A slower pace of weight loss can reduce the severity of skin changes.
  2. Stay Hydrated: Proper hydration keeps skin plump and improves elasticity.
  3. Support Skin Health with Nutrition: A diet rich in vitamins (like C and E) and collagen-boosting foods helps maintain skin’s resilience.
  4. Skincare Treatments:
    • Fillers: Restore lost volume in areas like the cheeks or under the eyes.
    • Non-invasive Procedures: Treatments like ultrasound or radiofrequency therapy can tighten sagging skin.
    • Topical Products: Retinoids, hyaluronic acid serums, and peptide creams can improve texture and hydration.

The Bottom Line

GLP-1 drugs are changing the game for diabetes and weight loss, but their effects on the skin remind us that every transformation comes with trade-offs. Understanding how these medications work and how they impact your skin can help you take proactive steps to care for both your health and your appearance.

author avatar
Dr. Jane Yoo Board-Certified Dermatologist and Mohs Surgeon
Jane Yoo, MD, MPP, is a Korean American board-certified dermatologist and fellowship-trained Mohs surgeon based in Midtown Manhattan. She is a Clinical Assistant Professor at the Icahn School of Medicine at Mount Sinai and the founder of Jane Yoo MD, PLLC and the Clinical Research Center of New York. Dr. Yoo holds an undergraduate degree from MIT and a Masters of Public Policy from Harvard's Kennedy School of Government. She completed her Mohs micrographic surgery fellowship at Yale. Her clinical and research focus spans aesthetic clinical trials including injectables and laser technology, skincare formulation and sunscreen science, K-Beauty and skin of color, ultrasound guided filler dissolution, artificial intelligence and beauty tech. Dr. Yoo's research is indexed under ORCID 0000-0002-7112-8963.